What is the current price of BRN.AX stock and why did it move today?

BRN.AX stock is trading at **A$0.14** intraday on 06 Mar 2026. The move of **+3.70%** reflects post-earnings positioning and short-term buying on hopes of Akida commercial traction following the 04 Mar 2026 earnings release.

How does Meyka AI rate BRN.AX and what does that mean?

Meyka AI rates BRN.AX **68.94/100 (Grade B) — Suggestion: HOLD**. The score weighs benchmark and sector comparisons, growth, metrics and consensus. It signals cautious interest but not a clear buy until revenue gains accelerate.

What are the main risks for BrainChip (BRN.AX)?

Main risks include continued negative earnings, a high price-to-sales multiple, slow commercial adoption of Akida, and limited average liquidity. Any missed revenue or partner updates can increase downside volatility.

What price targets should traders watch for BRN.AX?

Traders can watch a near-term target of **A$0.16** and a medium target of **A$0.20**, with a downside risk level near **A$0.08** if adoption stalls. Use stops and position sizing given volatility.

AU Stocks

BRN.AX up 3.70% to A$0.14 on ASX 06 Mar 2026: Edge AI earnings catalyst ahead

ByHuzaifa Zahoor March 6, 2026

The BRN.AX stock moved higher intraday to A$0.14, up 3.70% on the ASX on 06 Mar 2026 as the market reacts to near-term earnings and edge-AI demand signals. Volume at 3,984,538 shares is below the 50-day average but jumped from the open of A$0.135. Investors are watching BrainChip Holdings Ltd (BRN.AX) for proof of commercial traction for its Akida neuromorphic chips and for any revenue lift from recent partnerships and the 04 Mar 2026 earnings announcement.